Medios expands „Advanced Therapies“ field and appoints Dr. Andreas Schmiede as Vice President

EQS-News: Medios AG / Key word(s): Personnel/Expansion Medios expands „Advanced Therapies“ field and appoints Dr. Andreas Schmiede as Vice President 05.08.2024 / 10:32 CET/CEST The issuer is solely responsible for the content of this announcement. Medios expands „Advanced Therapies“ field and appoints Dr. Andreas Schmiede as Vice President

Berlin, August 5, 2024 – Medios AG (“Medios“), a leading provider of Specialty Pharma in Europe, strengthens its activities in the field of Advanced Therapies and appoints Dr. Andreas Schmiede as Vice President Advanced Therapies. The entry into the Advanced Therapies market is the next step in the implementation of the expanded growth strategy announced in November 2022 and reflects the Medios Group's ambition to make pharmaceutical innovations available to patients. Medios aims to exploit the enormous potential of cutting-edge healthcare technologies in the field of “Advanced Therapies” and thus generate additional added value for society. At the same time, the company increases the degree of diversification of its business model and strengthens its leading position in the European Specialty Pharma market.

Matthias Gaertner, CEO of Medios AG: “The strategic expansion of our leadership team represents a significant milestone in our efforts to further drive innovation and excellence in individualized and personalized medicine. We are delighted to announce the appointment of Dr. Andreas Schmiede as our new Vice President Advanced Therapies. His extensive expertise will make a decisive contribution to our goal of successfully shaping the future of personalized medicine.“

The company will use its state-of-the-art GMP (Good Manufacturing Practice) laboratories in Germany and Europe as well as its existing expertise in compounding to make high-quality personalized therapies available to patients by collaborating in particular with pharmaceutical and biotech companies, contract manufacturers (CMO), developers, patient organizations and payers. Medios is thus also supporting the German government's “National Strategy for Gene- and Cell-Based Therapies” published in June 2024, which aims to make innovative treatment methods for rare and serious diseases more readily available in Germany as a business location. This initiative offers opportunities for Medios as a leading provider of Specialty Pharma solutions in Germany and improves patient access to advanced therapies.